VERTEX PHARMACEUTICALS INC / MA Net Income Loss

• VERTEX PHARMACEUTICALS INC / MA showed an increase of +838.1% in Net Income Loss from 2024 to 2025.
• This data is from VERTEX PHARMACEUTICALS INC / MA's annual report (Form 10-K), filed with the SEC on February 13, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), VERTEX PHARMACEUTICALS INC / MA's Net Income Loss has grown by 715.6%.
• Historical annual values: Fiscal year 2025: $3.95 billion | Fiscal year 2024: -$535.60 million | Fiscal year 2023: $3.62 billion | Fiscal year 2022: $3.32 billion | Fiscal year 2021: $2.34 billion | Fiscal year 2020: $2.71 billion | Fiscal year 2019: $1.18 billion | Fiscal year 2018: $2.10 billion | Fiscal year 2017: $263.48 million | Fiscal year 2016: -$112.05 million | Fiscal year 2015: -$556.33 million | Fiscal year 2014: -$738.56 million | Fiscal year 2013: -$445.03 million | Fiscal year 2012: -$107.03 million | Fiscal year 2011: $29.57 million | Fiscal year 2010: -$754.63 million | Fiscal year 2009: -$642.18 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026